Auris Medical secures $50.6 Million in Series C financing deal.
Pharmaceutical company, Auris Medical, has secured CHF 47.1 m ($50.6 million) in a Series C financing deal from Sofinnova Ventures and Sofinnova Partners to advance ground-breaking therapy for inner ear problems, such as tinnitus, through Phase III clinical development.
Two leading venture capital firms, Sofinnova Ventures and Sofinnova Partners participated in the financing deal.
Financing will enable the pharmaceutical company to advance its two clinical projects, AM-101 for the treatment of acute tinnitus and AM-111 for the treatment of acute inner ear hearing loss, through Phase III studies and ultimately to market launch.
For further deal information visit Current Agreements (subscription required)
View: Current Partnering Financing Deals - the latest financing deals in life sciences
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
Read: latest life science partnering, M&A, financing and deal talk updates